Replies to post #159723 on Biotech Values

[DewDiligence]

XOMA—Considering the Eyegate Ph3 trial only matched SOC, I'm wondering if XOMA will eventual run a trial in anterior uveitis?

If Gevokicumab works in (non-anterior) NIU, it should also work in anterior disease; however, the unmet medical need is not as great in anterior disease, where generic steroids do an adequate job very cheaply.